We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Entasis Therapeutics Holdings Inc | NASDAQ:ETTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.19 | 2.21 | 2.19 | 0 | 01:00:00 |
Details of the presentation are below: | |
Event: | 28th Annual Credit Suisse Healthcare Conference |
Location: | The Phoenician |
Date: | Tuesday, November 12, 2019 |
Time: | 4:45 – 5:15 PM MST |
Additionally, Dr. Gutch will hold 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Credit Suisse representatives.
About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com
Investor Relations Contact Tram Bui The Ruth Group (646) 536-7035 tbui@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com
1 Year Entasis Therapeutics Chart |
1 Month Entasis Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions